Perspective Therapeutics (CATX) Study update summary
Event summary combining transcript, slides, and related documents.
Study update summary
25 Oct, 2026Study design
Ongoing Phase 1/2a dose-escalation and exploration study in PRRT-naïve, SSTR2-positive NET patients; interim analysis covered 68 patients in Cohorts 1–3, treated with up to four doses of 2.5, 5.0 or 6.0 mCi.
Cohort 4 is enrolling with a frontloaded 6/5/5/4 mCi regimen, described as a modified 20 mCi approach.
Data cutoff was 10 Sep 2026; analyses were interim and investigator-assessed, with shorter follow-up in Cohort 3 than Cohort 2.
Clinical activity
Investigator-assessed ORR, including unconfirmed responses, was 32.6% in Cohort 2 (5.0 mCi; 15/46) and 50.0% in Cohort 3 (6.0 mCi; 10/20); confirmed PR rates were 30.4% and 30.0%, respectively.
DCR was 89.1% in Cohort 2 and 95.0% in Cohort 3; among GEP-NET patients with SSTR2 expression in all target lesions, ORR was 36.8% in Cohort 2 and 47.1% in Cohort 3.
Across Cohorts 1–3, estimated PFS was 71.9% at 18 months (95% CI 58.3–81.8), 74% at 12 months and 86% at 6 months; Cohort 2 PFS was 68.9% at 18 months.
Cohort 3 responses were higher at early assessments; responses were observed as late as 60 weeks, and tumor response and PFS follow-up continue to mature.
Safety and tolerability
No dose-limiting toxicities, Grade 4 or 5 TEAEs, treatment-related serious AEs or treatment-related discontinuations; no dysphagia, clinically significant myelosuppression or myelodysplastic syndrome was reported.
Grade 3 TEAEs occurred in 20/68 patients (29%); Grade 3 acute kidney injury occurred in 2 patients (2.9%). Investigators assessed one case as unlikely related and one as possibly related; one resolved and one was ongoing.
Common TEAEs included alopecia (67.6%), fatigue (66.2%), nausea (64.7%) and diarrhoea (42.6%); alopecia was usually mild and reversible.
Low-grade thrombocytopenia and transient leukopenia were observed; blood-cell counts generally recovered within one treatment cycle.
Latest events from Perspective Therapeutics
- Clinical programs advanced on interim signals, with $201.7M expected to fund operations into 2028.CATX
Q3 2026 - VMT-α-NET showed up to 50% ORR with no Grade 4 or 5 TEAEs.CATX
Morgan Stanley 24th Annual Global Healthcare Conference - Cash of $236.9M supports clinical expansion as net loss widens with R&D and manufacturing growth.CATX
Q2 2026 - Alpha emitter therapy shows high efficacy and safety in NETs, with phase III readiness advancing.CATX
RBC Capital Markets Global Healthcare Conference 2026 - VMT-α-NET demonstrates high response rates as pivotal trial planning and manufacturing expansion progress.CATX
Bank of America Global Healthcare Conference 2026 - Net loss increased to $26.2M as R&D ramped up, with cash rising to $271M after equity raise.CATX
Q1 2026 - Director elections, auditor ratification, and annual say-on-pay vote set for May 2026.CATX
Proxy filing - 44% response rate and durable disease control in SSTR2+ NETs with strong safety profile.CATX
Study Update - Lead-212 platform advances with expanding manufacturing and promising early clinical results.CATX
Barclays 27th Annual Global Healthcare Conference